Introduction {#sec1}
============

Oral squamous cell carcinoma (OSCC) constitutes 90% of oral cavity malignancies. More importantly, early diagnosis is associated with improved prognosis and survival rate.^[@ref1]^ Late diagnosis and metastasis lead to a decreased 5 year survival rate of 9% for OSCC.^[@ref2]^ If OSCC patients are diagnosed early and treated before lymph node metastasis, the survival rate increases to between 60 and 85%.^[@ref2],[@ref3]^ Oral potentially malignant disorder (OPMD) consists of several phenotypes, including oral submucous fibrosis, hyperplasia, leukoplakia, erythroleukoplakia, and erythroplakia. The incidence of OPMD progressing into OSCC is between 4 and 22%.^[@ref4]^ Notably, the risks of progression to OSCC are 42.2 and 95% for leukoplakia and erythroleukoplakia, respectively, after 20 years of follow-up.^[@ref5]^ Therefore, early diagnosis and treatment is crucial for improving prognosis.^[@ref6]^

Nowadays, the choices for OPMD treatment include surgical excision and CO~2~ laser, but both are invasive approaches. Although surgical excision can remove more tissue area to prevent the progression into OSCC, it may lead to scarring and contracture. CO~2~ laser offers the advantage of reducing scarring but does not provide tissue specimens for histopathology assessment.^[@ref7]^ More importantly, the recurrence rate after CO~2~ laser treatment is 17--34%, which is relatively high.^[@ref8]^ Therefore, manufacturing a convenient and non-invasive Orabase-formulated drug may improve the patient's treatment compliance.

Benzalkonium chloride (BAK) is a quaternary ammonium compound used as a cationic surfactant and antimicrobial preservative.^[@ref9]^ Solutions containing BAK are widely applied against bacteria, yeast, and fungi.^[@ref10],[@ref11]^ BAK has three main uses including being a biocide, a cationic surfactant, and a phase transfer agent.^[@ref12]^ It is the most common preservative in ophthalmic, nasal, and otic products. However, BAK is rarely intended for other routes of administration, such as oral, cutaneous, vaginal, and rectal. Moreover, the use of BAK in oral precancerous lesions treatment has not been previously reported.

Recently, finding new bioactivities from previously approved drugs has been accomplished by high-throughput screening (HTS) library, which is referred to as drug repurposing.^[@ref13]^ In this study, a cell-based HTS assay was applied to screen clinical drugs for new indications, which showed that benzalkonium chloride (BAK) was able to kill oral precancerous cells in vitro and in vivo.

Results {#sec2}
=======

Identifying Compounds with Anti-Oral Precancer Activity Using HTS {#sec2.1}
-----------------------------------------------------------------

The primary screening process was performed in 1536-well plates following optimization of various parameters, including number of DOK cells (2000), incubation time (72 h) and FBS concentration (2%) in order to screen 122,323 compounds ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A). Based on the activity profile of these compounds, 2814 hits, which demonstrated an activity of \<0.35, were selected for IC50 determination ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). A total 1164 compounds that showed good dose-dependent activity were identified from these 2814 hits (*R*^2^ \> 0.8) (data not shown). From the primary screening process, 239 compounds were selected for secondary screening to evaluate their IC~50~ in 384-well plates. At the end of the secondary screening process, 41 compounds were found to fulfil the following three criteria: high cytotoxic activity against oral precancerous cells, potential for topical administration, and not previously used for cancer treatment. After HTS screening, the selected compounds were used for cell-based experiments, and the new Orabase formulations were used for animal experiments. Because cisplatin is a commonly used clinical drug for oral cancer, it was used as a control to analyze the anti-precancer activity of the selected compounds. According to the results from the primary and secondary screening processes, the IC~50~ of BAK was 0.56 μM, which was much lower than cisplatin (IC~50~ 20 μM) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C).

![Anti-oral precancer activity from clinical drugs was screened by HTS. (A) Flowchart for the HTS assay. (B) Primary screening hits, which demonstrated an activity of \<0.35, were selected. (C) IC~50~ of cisplatin and BAK in DOK cells.](ao0c00640_0001){#fig1}

Evaluation of Anti-Oral Precancer Activity of BAK {#sec2.2}
-------------------------------------------------

The chemical structure of BAK was presented in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A. We next assessed BAK-induced cell death in DOK cells. The percentage of cells in the sub-G1 phase was increased from 5 to 30% when the concentration of BAK was increased from 5 to 15 μM ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). To verify whether this was due to necrosis or apoptosis, we used Annexin V staining to distinguish the form of cell death. 10 μM BAK significantly increased the number of propidium iodide^+^/Annexin V^+^ DOK cells from 2 to 24 h ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C). Furthermore, we determined the expression of apoptotic proteins after treatment of DOK cells with 10 μM BAK. As seen in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D, the active cleaved forms of Caspase-7, Caspase-9, Caspase-3, and PARP were significantly increased in a time-dependent manner. In addition, the marker for DNA fragmentation, phospho-H2AX (γH2AX), was increased from 2 to 24 h.

![Anti-oral precancer activity of BAK in DOK cells. (A) Chemical structure of BAK. (B) Following treatment of DOK cells with BAK (5, 10, or 15 μM) for 24 h, propidium iodide-stained cells were evaluated by flow cytometry. (C) DOK cells were treated with 10 μM BAK for 2, 8, and 24 h, stained with propidium iodide/Annexin V, and evaluated by flow cytometry. (D) Apoptotic proteins expression was analyzed by immunoblotting after treatment of DOK cells with 10 μM BAK for 2, 8, and 24 h. β-actin was used as the loading control. Columns were the mean from three independent experiments and error bars indicate SE. \**p* \< 0.05; \*\*\**p* \< 0.0005.](ao0c00640_0002){#fig2}

BAK Induced Oral Precancer Cell Death through Stimulating ROS Production and Suppressing pSTAT3 and pAkt {#sec2.3}
--------------------------------------------------------------------------------------------------------

Next, we studied the underlying mechanisms involved in BAK-induced apoptosis in oral precancer cells. The accumulation of reactive oxygen species (ROS) could result in increased level of γH2AX through causing DNA breaks.^[@ref14]^ Since we found that the level of γH2AX was increased in BAK-treated DOK cells, we next determined the intracellular ROS level using DCFDA and DHE assays. Our results showed that treatment of DOK cells with BAK led to increased DCFDA and DHE levels ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). ROS production has been previously found to induce apoptosis through suppressing the phosphorylation of STAT3 in hepatocellular carcinoma.^[@ref15]^ Therefore, we determined the level of p-STAT3 (Tyr705) in DOK cells treated with BAK. As seen in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B, the level of p-STAT3 (Tyr705) was decreased following BAK treatment. To verify whether STAT3 played a role in cell death induced by BAK, the STAT3 inhibitor Stattic was used to suppress STAT3 activity ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00640/suppl_file/ao0c00640_si_001.pdf)). STAT3 inhibitor increased the cell death ratio from 50 to 70% in BAK-treated DOK cells ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). It is also known that PI3K/Akt is an important signaling pathway for cell survival.^[@ref16]^ As seen in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B, the level of p-Akt (Ser473) in DOK cells was decreased, following treatment with different doses of BAK from 5 to 15 μM. Combined treatment of DOK cells with Wortmannin, a PI3K/Akt inhibitor, and BAK resulted in increased cell death ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D).

![BAK-induced oral precancerous cell death through stimulating ROS production and suppressing pSTAT3 and pAkt. (A) Following treatment of DOK cells with BAK (5 μM, 10 μM or 15 μM) for 4 h, the ROS level was measured by flow cytometry. (B) Expression of p-STAT3 (Tyr705), STAT3, p-Akt (Ser473), and Akt in DOK cells treated with different concentrations of BAK for 4 h. β-actin was used as the loading control. (C) DOK cells were treated with 2 μM Stattic alone or in combination with 10 μM BAK for 48 h, and cell viability was measured by XTT. (D) DOK cells were treated with 0.1 mM Wortmannin alone or in combination with 10 μM BAK for 48 h. Cell viability was measured by XTT. Columns were the mean from three independent experiments, and error bars indicate SE. \* *p* \< 0.05 \*\*\**p* \< 0.0005.](ao0c00640_0004){#fig3}

BAK Suppressed Oral Precancerous Lesions Development In Vivo {#sec2.4}
------------------------------------------------------------

We used hamsters as an animal model to investigate the effect of BAK on the development of oral precancerous lesions. The preparation of Orabase-formulated BAK and the experimental procedure for the hamster model are described in the [Methods](#sec4){ref-type="other"} section, and the experimental protocol is presented in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A. The macroscopic features of the buccal pouch between Group A (hamsters with no treatment) and Group B (hamsters treated with BAK only) were similar ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Although oral lesions were seen in Group C (hamsters treated with DMBA only), no obvious lesions were found in Group D (hamsters treated with DMBA followed by 2% BAK) ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). Additionally, histological examination of Group C lesions demonstrated epithelial hyperplasia and moderate to severe epithelial dysplasia. In contrast, the histological examination of buccal pouch tissues from Group D showed only slightly thickened lamina propria ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B). After treatment with BAK for 3 weeks, the tumor volume in Group D was found to be smaller than Group C ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C). It was worth noting that biomedical parameters and body weight did not differ significantly between Groups C and D ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00640/suppl_file/ao0c00640_si_001.pdf)).

![BAK-inhibited oral precancerous lesions development. (A) Experimental design protocol. (B) Hematoxylin--eosin stains and photographs from the four experimental groups: Group A (hamsters with no treatment), Group B (hamsters treated with BAK only), Group C (hamsters treated with DMBA only), and Group D (hamsters treated with DMBA followed by 2% BAK). (C) Tumor volumes from Groups C and D were calculated based on the formula (width^2^ × length)/2. \**p* \< 0.05 \*\*\**p* \< 0.0005.](ao0c00640_0005){#fig4}

Discussion {#sec3}
==========

In this study, we found by HTS screening that the clinically used drug benzalkonium chloride (BAK) exhibited apoptotic activity against DOK oral precancer cells, which was mediated by ROS production and inhibition of STAT3 and Akt signal transduction pathways. In addition, we manufactured a new Orabase-formulated BAK, which suppressed oral precancerous lesions development in hamsters.

HTS is a well-known technology that has been used for identifying new biological activities from clinical drugs over the past 20 years. In particular, HTS has been applied in the discovery and development of several FDA-approved drugs for cancer therapy.^[@ref17]^ The HTS platform for small molecule screening has several advantages, including low-volume assay, parallel data generation, cost-effectiveness, and shortened development timeline for drug repurposing.^[@ref18]^ In this study, we used the HTS assay to discover a new indication for BAK in causing apoptosis of oral precancerous cells.

In the field of oral diseases treatment, sustained release drug formulations with mucoadhesive characteristics can improve treatment efficacy, decrease drug wastage, reduce systemic side effects, and increase patient compliance.^[@ref19],[@ref20]^ Due to these benefits, topical oral gels have been extensively used as anti-inflammatory, anti-fungal, and mucoprotective formulations.^[@ref20]^ BAK has been commonly used in ophthalmic preparations as an effective anti-bacterial and fungicidal agent since the 1950s.^[@ref21]^ However, it has not been previously reported whether BAK may be effective in cancer therapy, especially for OPMD. In this study, we provide the first evidence that Orabase-formulated BAK may be an effective treatment modality for OPMD.

Drug repurposing is beneficial for identifying new clinical applications from FDA-approved drugs.^[@ref2]^ Because most repurposed drugs have already completed the safety assessment and preclinical testing stages, the time and cost for the approval of drug repurposing are significantly reduced.^[@ref22]^ According to our findings, we believe that this new formulation of Orabase BAK is a potential local and non-invasive treatment for OPMD.

Conclusions {#sec3.1}
-----------

Orabase-formulated BAK may be a potential topical, non-invasive, and function-preserving therapeutic strategy for OPMD lesions and may prevent their progression into oral cancer.

Materials and Methods {#sec4}
=====================

Cell Culture {#sec4.1}
------------

Human oral precancerous cells (DOK) were maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) with fetal bovine serum (10%), penicillin/streptomycin (100 U/mL), [l]{.smallcaps}-glutamine (1%) and non-essential amino acids (1%) in a 37 °C, 5% CO~2~ incubator.

High-Throughput Screening Assay {#sec4.2}
-------------------------------

1536-well plates were used for primary screening at the Genomics Research Center of Academia Sinica, Taiwan. To determine HTS assay criteria, various culture media and freezing media were evaluated, and the optimal condition was selected for large-scale screening. For the HTS assay, various cell numbers of DOK (100--5000 cells/well) in different FBS concentrations were added into 1536-well plates. Following incubation for 48 or 72 h, Cell TiterGlo (Promega) was used to evaluate cell proliferation. The CV% was determined as 8--10% and the *Z*′ value was determined as 0.63. The most effective primary hits were identified for secondary screening to determine IC~50~ values. DOK cells were treated with the compounds from primary hits at 10-point 3-fold serial dilutions, starting from 21 μM. After 72 h, Cell TiterGlo (Promega) was used to determine cell proliferation, and the values were used to calculate the IC~50.~

XTT Assay {#sec4.3}
---------

First, 5 × 10^[@ref3]^ DOK cells were seeded into 96-well plates and incubated overnight to allow cells to attach. After treatment of DOK cells with different drugs for 48 h, the XTT assay was used to analyze cell proliferation. The detailed procedures were in accordance with a previous study.^[@ref23]^

Cell Cycle Analysis {#sec4.4}
-------------------

First, 1.5 × 10^[@ref5]^ DOK cells were seeded into 6-well plates and incubated overnight to allow cells to attach. After treatment of DOK cells with different doses of BAK (5, 10, and 15 μM) for 24 h, harvested cells were stained with a propidium iodide solution (0.2 g/mL RnaseA, 0.02 mg/mL propidium iodide, and 0.05% Triton-X 100 in PBS) at room temperature for 10 min. The cell cycle distribution was analyzed by BeckmanCoulterFC500 and Flow Jo software.

Propidium Iodide/Annexin V Assay {#sec4.5}
--------------------------------

First, 1.5 × 10^5^ DOK cells were seeded into 6-well plates and incubated overnight. After treatment of DOK cells with BAK for 2, 8, and 24 h, harvested cells were stained with propidium iodide and Annexin V-FITC in a dark environment for 20 min. Stained samples were evaluated by BeckmanCoulterFC500 and Flow Jo software.

Western Blotting {#sec4.6}
----------------

First, 6 × 10^5^ DOK cells were seeded into 6 cm plates and incubated overnight. Following the treatment of DOK cells with BAK, Stattic, or Wortmannin, cell lysates were obtained and lysed in an RIPA buffer containing a proteinase inhibitor. The protein lysates were loaded onto SDS-PAGE, and proteins were transferred onto PVDF membranes and reacted with primary antibodies followed by secondary antibodies (Jackson, USA). Finally, the signals were amplified by ECL (Perkin Elmer, USA), imaged by ChemiDoc XRS+ System (BioRad, USA) and quantified by Image Lab software (BioRad, USA). Primary antibodies against pSTAT3(Tyr705), STAT3, pAkt(Ser473), Akt, cleaved caspase-3, cleaved caspase-9, cleaved caspase-7, cleaved PARP, γH2AX, and beta-Actin (GeneTex, USA) were used for Western blotting.

Reactive Oxygen Species (ROS) Detection {#sec4.7}
---------------------------------------

First, 1.5 × 10^5^ DOK cells were seeded into 6-well plates and incubated overnight. DOK cells were treated with different doses of BAK (5, 10, and 15 μM) for 4 h and stained with 10 μM DCFDA or DHE in a dark environment for 30 min. The mean fluorescence intensities were analyzed by BeckmanCoulterFC500 and Flow Jo software.

Orabase-Formulated Benzalkonium Chloride {#sec4.8}
----------------------------------------

HPMC4000 (5%) (Shin Etsu, Japan), ethanol (10%) (Merck, Germany), carbitol (10%) (Merck, Germany), BAK (2%) (Merck, Germany), and distilled water were used to manufacture Orabase-formulated BAK. First, BAK was dissolved in distilled water and mixed for \>12 h, and then 5% HPMC4000, 10% ethanol, and 10% carbitol were added into the mixture in sequence. Orabase-formulated BAK was stored inside a brown bottle.

Animal Study {#sec4.9}
------------

The animal study was approved by the Institutional Animal Care and Use Committee of Kaohsiung Medical University, Taiwan. Animal experiments were conducted according to the Animal Research: Reporting in Vivo Experiments (ARRIVE) guidelines. We used 7,12-dimethylbenz\[a\]anthracene (DMBA) (Merck, Germany) to induce oral precancerous lesions on the hamsters' buccal pouch (NLAC, Taiwan)^[@ref24],[@ref25]^ followed by 2% BAK treatment once weekly with the experimental protocol shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A. First, 16 male Syrian golden hamsters (Mesocricatus auratus), which weighed 80--100 g were randomly allocated into four different groups. Group A (*n* = 2) comprised hamsters with no treatment. Group B (i = 2) comprised hamsters treated with 2% BAK only. For the experimental groups (Groups C and D), 0.5% DMBA (in mineral oil) was applied 10 times onto the buccal pouch three times weekly for 9 weeks. Group C (*n* = 3) comprised hamsters treated with DMBA only. Group D (*n* = 9) comprised hamsters treated with DMBA followed by 2% BAK. At the 13th week, animals were sacrificed by Zoletil injection followed by CO~2~ asphyxiation. Tumor volume was determined once a week based on the following formula: (width^2^ × length)/2.

Hematoxylin--Eosin Staining {#sec4.10}
---------------------------

Excised buccal pouches from hamsters were fixed in 10% neutral-buffered formalin and embedded in paraffin. Tissue sections were stained with hematoxylin and eosin. Slides were washed briefly in distilled water and stained in a hematoxylin solution for 10 min followed by washing in running tap water for 5 min, 1% acid for 30 s and running tap water for 1 min, 0.2% ammonia water for 30 s, and washing was repeated as in the previous step. Slides were rinsed in 95% alcohol, counterstained in an eosin--phloxine solution for 30 s, and dehydrated in 95% alcohol twice for 5 min each. Slides were finally washed in xylene and mounted for viewing.

Statistical Analysis {#sec4.11}
--------------------

All experiments were performed at least three times. Quantitative data were presented as mean ± standard error (SE) from three independent experiments. To compare multiple groups, one-way analysis of variance (ANOVA) followed by post hoc Tukey's test was used. To compare two groups, the independent *t* test was employed. Statistical significance was defined as *P* value less than 0.05.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c00640](https://pubs.acs.org/doi/10.1021/acsomega.0c00640?goto=supporting-info).(S1) Phosphorylation levels of pAkt (S473) and pSTAT3 (T705) were suppressed by wortmannin and static and (S2) biological parameters in hamsters were not distinct from different groups ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c00640/suppl_file/ao0c00640_si_001.pdf))
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